Oramed Pharmaceuticals Reports Positive Results From a Study of Oral Insulin Capsule on Type 1 Diabeti...( JERUSALEM Israel July 21 /- Orame...)

JERUSALEM, Israel, July 21 /PRNewswire-FirstCall/ -- Oramed Pharmaceuticals, Inc. (OTCBB: ORMP.OB) ( http://www.oramed.com), a developer of alternative drug delivery systems, today reported positive results from a Phase 2A study of its oral insulin capsule, ORMD-0801, on type 1 diabetic patients. The completion of this study marks Oramed's first clinical trial on patients with Type 1 Diabetes Mellitus, whereas, all Oramed's trials up to date have been conducted on type 2 diabetic patients. This study evaluated safety, tolerability, and food effects in type 1 diabetic patients.

Oramed's oral insulin capsule, (ORMD-0801), was well tolerated by patients and no serious adverse events were observed. The insulin absorption was not affected when given before meal ingestion.

Oramed Chief Scientific Officer, Miriam Kidron, PhD., remarked, "These results demonstrate that Oramed's oral insulin capsule had a good safety profile and was effective on patients with type 1 diabetes when taken prior to a meal."

Currently, Oramed is conducting its Phase 2B clinical trial in South Africa, in which the company is evaluating the effects of ORMD-0801 on type 2 diabetic patients.

About Oramed Pharmaceuticals

Oramed Pharmaceuticals is a technology pioneer in the field of oral delivery solutions for drugs and vaccines presently delivered via injection. Oramed is seeking to revolutionize the treatment of diabetes through its patented flagship product, an orally ingestible insulin capsule currently in phase 2 clinical trials. Established in 2006, Oramed's technology is based on over 25 years of research by top research scientists at Jerusalem's Hadassah Medical Center. The Company's corporate and R&D headquarters are based in Jerusalem.

For more information, please visit http://ww
'/>"/>